Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressiv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Witzig, Thomas E., Tang, Hui, Micallef, Ivana N. M., Ansell, Stephen M., Link, Brian K., Inwards, David J., Porrata, Luis F., Johnston, Patrick B., Colgan, Joseph P., Markovic, Svetomir N., Nowakowski, Grzegorz S., Thompson, Carrie A., Allmer, Cristine, Maurer, Matthew J., Gupta, Mamta, Weiner, George, Hohl, Ray, Kurtin, Paul J., Ding, Husheng, Loegering, David, Schneider, Paula, Peterson, Kevin, Habermann, Thomas M., Kaufmann, Scott H.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2011
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208296/
https://ncbi.nlm.nih.gov/pubmed/21725056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-334904
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars